

# Diabetes & Obesity

## RESEARCH REVIEW™

Making Education Easy

Issue 134 – 2020

### In this issue:

- Gout risk with SGLT-2 inhibitors in type 2 diabetes
- Antimicrobial stewardship in DKA
- Lifetime glycaemic control in patients with type 1 diabetes from Waikato
- Risk prediction model for early diabetic kidney disease
- Cyclical topical wound oxygen therapy for diabetic foot ulcers
- Effects of bariatric surgery in early- and adult-onset obesity
- Church-based lifestyle intervention for Samoans
- Low-energy, low-carbohydrate diet in type 2 diabetes
- Inhibition of food craving: a neurological metabolically active process
- Glucose-lowering medications and CV outcomes

#### Abbreviations used in this issue

**BMI** = body mass index  
**BP** = blood pressure  
**CV** = cardiovascular  
**DKA** = diabetic ketoacidosis  
**GLP** = glucagon-like peptide  
**HbA<sub>1c</sub>** = glycosylated haemoglobin  
**HF** = heart failure  
**RCT** = randomised controlled trial  
**SGLT** = sodium glucose cotransporter

## Welcome to issue 134 of Diabetes and Obesity Research Review.

This issue begins with research reporting a lower risk of gout in recipients of SGLT-2 inhibitors (for type 2 diabetes) than GLP-1 receptor agonist recipients. NZ research is included in the form of a retrospective review describing differences in glycaemic control according to age, gender, rurality and ethnicity in patients with type 1 diabetes from the Waikato region. Also relevant to NZ's Pacific population is research from our trans-Tasman neighbours reporting on the value of a church-based lifestyle intervention programme targeting Samoans living in Sydney. This issue concludes with a large umbrella analysis of meta-analyses providing us with a comprehensive assessment of CV outcomes associated with a range of glucose-lowering medications.

We hope you enjoy this update in diabetes and obesity research, and our recent special report on COVID-19 and diabetes. We would be delighted to hear your thoughts and feedback.

Best regards,

**Professor Jeremy Krebs**

[jeremykrebs@researchreview.co.nz](mailto:jeremykrebs@researchreview.co.nz)

### Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes

**Authors:** Fralick M et al.

**Summary:** Gout rates were compared between cohorts of adults newly prescribed SGLT-2 inhibitors versus GLP-1 receptor agonists for type 2 diabetes in this population-based study using US insurance claims data (n=295,907). Compared with propensity score-matched GLP-1 receptor agonist recipients, SGLT-2 inhibitor recipients had a significantly lower incidence rate of gout (4.9 vs. 7.8 events per 1000 person-years; hazard ratio 0.64 [95% CI 0.57, 0.72]).

**Comment:** Gout is a common comorbidity of type 2 diabetes and very relevant in NZ, with Māori more likely to have both conditions. There is increasing evidence for additional – non-glucose-lowering – CV and renal benefits of the SGLT-2 inhibitor class of medications that have been well reported and discussed previously. Blockade of SGLT-2 not only reduces glycaemia, but also reduces serum uric acid levels, which may therefore reduce the incidence of gout. This study focuses on this question, using an insurance database from the US, and a propensity matching design as opposed to a true RCT. That said, the sample size was very large, with almost 300,000 people split between those starting an SGLT-2 inhibitor or a GLP-1 agonist. There were 40% fewer new cases of gout in those using an SGLT-2 inhibitor, but the overall rates were actually very low. How this might translate to the NZ context, and particularly for Māori, would be very interesting. The benefits may potentially be greater, and when combined with reduced risks of CV events and renal failure, may significantly improve equity.

**Reference:** *Ann Intern Med* 2020;172:186–94

[Abstract](#)



### Covid-19 Response: Our heartfelt thanks


All of us at Research Review want to thank you for the part you are playing in the Covid-19 crisis. Our hats go off to you, and we are proud to be associated with you. Our role in all of this is to support you by keeping you informed and up to date as much as we possibly can.

## OBESITY IS GLOBALLY RECOGNISED AS A CHRONIC DISEASE<sup>1</sup>

### CONSIDER DUROMINE™ TO HELP YOUR PATIENTS ACHIEVE THEIR WEIGHT LOSS<sup>2</sup> GOALS AND IMPROVE THEIR HEALTH

**References:** 1. World Health Organization. Obesity: preventing and managing the global epidemic. Technical Report 894. 2000. 2. Duromine Data Sheet. 2018. New Zealand. **DUROMINE™** IS A C5 CONTROLLED DRUG. DUROMINE™ IS AN UNFUNDED MEDICINE - A PRESCRIPTION CHARGE WILL APPLY. PLEASE REVIEW FULL DATA SHEET BEFORE PRESCRIBING AVAILABLE AT [WWW.MEDSAFE.GOVT.NZ](http://WWW.MEDSAFE.GOVT.NZ) OR PHONE Freephone 0508 375394. Minimum Data Sheet Information (phentermine). **DUROMINE™** Indications: For the management of obesity as a short-term adjunct in a medically monitored weight loss programme based on exercise, diet and behaviour modification in obese patients with a body mass index (BMI) of 30 kg/m<sup>2</sup> or greater. **DUROMINE™** may appropriately be initiated in overweight patients with a lower BMI when risk of morbidity from other medical conditions is increased. **Dosage and Administration:** The usual starting dose in adults and children over 12 years is 30 mg once daily at breakfast. Continuous or intermittent maintenance dose is 15 mg to 30 mg once daily depending on responsiveness. Patients require medical review after a defined course of treatment, which should not exceed three months. Available in 15 mg and 30 mg capsules. **Contraindications:** Pulmonary artery hypertension, heart valve abnormalities, heart murmurs, moderate to severe hypertension, cerebrovascular disease, severe cardiac disease including arrhythmias, advanced arteriosclerosis, hypersensitivity to sympathomimetic drugs, hyperthyroidism, psychiatric illnesses, glaucoma, drug/alcohol abuse or dependence, concomitant MAOIs or within 14 days of MAOI use. **Precautions:** Short term monotherapy only. Co-administration of drug products for weight loss is not recommended. There have been no reported cases of valvular heart disease occurring with phentermine alone. Use with caution in mild hypertension, established coronary artery disease, epilepsy, and in those receiving insulin, oral hypoglycaemic agents or psychotropic agents. **Adverse Effects:** The most common are palpitations, tachycardia, elevation of blood pressure and precordial pain. Others included restlessness, insomnia, nausea, and dry mouth. Psychotic episodes, hallucinations and serious cardiovascular or cerebrovascular events are rare. Full Data Sheet and Consumer Medicine Information is available from Medsafe at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). ©Nova Pharmaceuticals (Australia) Pty Limited, Level 10, 12 Help Street, Chatswood NSW 2067, Australia. Distributed in New Zealand by Radiant Health Ltd, c/o Supply Chain Solutions, 74 Westney Road, Airport Oaks, Auckland. For all product enquiries: New Zealand Toll Free: 0508 375 394. TAPS NA 11718. NZ2020-03-0009, March 2020.

**DUROMINE™**  
PHENTERMINE



For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.researchreview.co.nz](http://www.researchreview.co.nz)

a RESEARCH REVIEW™ publication



## Antimicrobial stewardship in diabetic ketoacidosis

**Authors:** Gassiep I et al.

**Summary:** This retrospective chart review of 111 patients with type 1 diabetes who presented with DKA a combined total of 249 times to a single centre reported on infections precipitating DKA, microbiological aetiology and antimicrobial prescribing practices over a ~3-year period ending mid-2018. Infections were suspected for 40% of the presentations, with 14.5% being proven or probable infections. Skin and soft tissue infections were present in 25% of presentations, UTIs in 22% and respiratory tract infections in 19%. Of 100 presumed infections, pathogens were identified in 24; these included *Staphylococcus aureus* (46%), *Klebsiella pneumoniae* (17%) and *Escherichia coli* (13%); no viral pathogens were detected. Three-quarters of the 80 prescriptions for empirical antimicrobials did not conform with guidelines for the management of suspected infections. Single-agent ceftriaxone was the most frequently prescribed antimicrobial, and was appropriately prescribed in 30% of cases.

**Comment:** Historically, infection has been the most common trigger of ketoacidosis in people with type 1 diabetes. I teach medical students to hunt hard for a source of infection once they have addressed fluids, insulin and potassium. This report from northern Australia suggests that infection may not be as common a trigger as we might imagine. This retrospective audit of over 100 cases of DKA revealed only 15% of confirmed infections, with the majority of cases of DKA precipitated by poor adherence to insulin regimens. It also demonstrated inappropriate antibiotic prescription in many of the cases of DKA that were not related to infection. Therefore, whilst we must be vigilant and continue to actively look for infection, care must be exercised in use of antibiotics where none is found, with more targeted questioning about adherence and/or self-harm.

**Reference:** *Intern Med J* 2020;50:173–7

[Abstract](#)

## Glycaemic control across the lifespan in a cohort of New Zealand patients with type 1 diabetes mellitus

**Authors:** Tamatea JAU et al.

**Summary:** Differences in glycaemic control according to age, gender, rurality and ethnicity were retrospectively reviewed for 1303 patients with type 1 diabetes entered into the Waikato Regional Diabetes Database. The patients' median HbA<sub>1c</sub> level was 67 mmol/mol (8.3%) with those aged 15–29 years having the highest levels and 85.3% of all patients having a level that exceeded clinical recommendations. Patients on insulin pump therapy had a lower median HbA<sub>1c</sub> level than those receiving multiple daily injections (63 vs. 69 mmol/mol, or 7.9% vs. 8.5% [ $p < 0.001$ ]), although Māori and males were significantly less likely to be on insulin pump therapy (respective  $p$  values 0.003 and  $< 0.0001$ ). An association was seen between worsening glycaemic control and increasing social deprivation ( $p < 0.001$ ); this was not influenced by rural versus urban living.

**Comment:** The evidence for the benefit of tight glycaemic control in type 1 diabetes dates back several decades. However, despite this and advances in available insulins and technology for monitoring glucose and administering insulin, people with type 1 diabetes continue to struggle to achieve their goal. This is further highlighted in this paper from Waikato, where 85% of people had an HbA<sub>1c</sub> level above target. It is notable that young adults had the highest HbA<sub>1c</sub> levels, an observation that we all see in our clinics. The authors point to Māori ethnicity and social deprivation as important factors, as well as reduced access to pumps. Whilst these may accentuate the difficulties people face, I think it is more complex than this when 85% do not meet their target. Managing type 1 diabetes is tough and relentless, no matter who you are.

**Reference:** *Intern Med J*; Published online March 16, 2020

[Abstract](#)

## Choose to add in Lantus for Type 2 Diabetes patients with an HbA<sub>1c</sub> of >65mmol/mol<sup>1#</sup>

### Reasons to use Lantus.

Lantus® once-daily in Type 2 Diabetes<sup>2</sup>:

- Has proven efficacy in reducing HbA<sub>1c</sub><sup>2-4</sup>
- Is associated with a lower risk of hypoglycaemia compared with NPH<sup>5-7</sup>
- Is easy to initiate and for patients to self titrate<sup>8</sup>
- Is a basal insulin with long-term CV safety data<sup>4,9</sup>

#After Lifestyle and oral diabetes medication optimisation



**References:** 1. Primary Care Handbook.2012. Ministry of Health. NZ. 2. Lantus Data Sheet. 31 July 2017. 3. DeVries J H. *Eur Endocrinol* 2014;10(1):23-30. 4. Gerstein HC, et al. *N Engl J Med* 2012;367:319-28. 5. Bazzano L A, et al. *Diabetic Medicine* 2008;25:924-932. 6. Horvath K, et al. *Long acting insulin analogues vs NPH insulin (Human isophane insulin) for Type 2 Diabetes Mellitus. Cochrane Review* 2009. 7. Home P.D, et al. *Diabetes, Obesity and Metabolism*. 2010; 12:772-779. 8. Davies M et al. *Diabetes Care*. 2005; 28:1282-88. 9. Melanie J. Davies et al. *Diabetes Care* 2018;41:2669-2701.

Lantus® Abridged Data Sheet

Please review Full Data Sheet before prescribing – available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz) or from the sponsor.

**Lantus®** (insulin glargine). **Indication:** Once-daily subcutaneous administration for type 1 and type 2 diabetes mellitus patients who require insulin for control of hyperglycaemia. **Contraindications:** Hypersensitivity to insulin glargine or any excipient. **Precautions:** Hypoglycaemia, possibly with delayed recovery or altered warning symptoms; hepatic, renal and visual impairment; lipodystrophy and other injection site or immediate-type allergic reactions; antibody production; not studied in children <6 years, pregnancy category B3, lactation; not intended for i.v. use; not recommended for treatment of diabetic ketoacidosis; LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. Patient instruction on intercurrent conditions, blood glucose monitoring, injection technique recommended. **Interactions:** Oral antidiabetic agents; cardiovascular, analgesic, anti-inflammatory, neurological, antipsychotic agents, antibiotics, corticosteroids, other hormonal therapies, diuretics, protease inhibitors, sympathomimetic agents, lithium, alcohol, sympatholytics including β-blockers, others. **Adverse effects:** Hypoglycaemia; injection site reactions; visual disturbances; others. **Dosage and Administration:** Subcutaneous, once daily; abdominal, thigh or deltoid administration; blood glucose monitoring is recommended. Lantus® is equipotent to human insulin. Initial dose should be determined individually, depending on desired blood glucose levels and doses and timing of any antidiabetic medication, including Lantus®. For changeover from once-daily NPH initial dose usually not changed; for changeover from twice-daily NPH to once-daily Lantus®, initial dose usually reduced by approximately 20% compared to total daily NPH dose; for initiation of type 2 patients, initial dose is usually approximately 10IU. For secondary dose adjustments, renal, hepatic impairment see full Data Sheet. **Medicine Classification:** Prescription Medicine. Presentations: Lantus® (insulin glargine injection) 100 U per mL is available in packs of 5x3mL cartridges, 5x3mL cartridges in SoloStar pre-filled pens and 10mL vials. **Sponsor:** Sanofi New Zealand, Level 8, 56 Cawley Street, Ellerslie, Auckland. Free phone 0800 283 684. Lantus® is a Funded Medicine. TAPS PP5272 SAAANZ.GLA.18.12.0593a(1). Date of preparation February 2020.

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)



## New subsidised needle quantities for people with diabetes<sup>1</sup>

General Practitioners can now write a single prescription for 200 needles (2 boxes of 100 needles).<sup>1</sup>

A repeat prescription for a second box of 100 needles is no longer required.

Maintaining needle coverage for patients on injection therapy:<sup>1</sup>

No. of daily injections	No. of prescriptions required from GP	No. of dispensed needles by Pharmacy
2 injections	1x prescription = 200 needles	1 visit = 200 needles
3 or more injections	2x prescriptions = 400 needles	2 visits = 200 needles each visit



For patient support materials please contact our BD Customer Service team at [bd\\_diabetes\\_care\\_ANZ@bd.com](mailto:bd_diabetes_care_ANZ@bd.com) or by phone on 0800 572 468.

Reference: 1. NZ Pharmaceutical Schedule Update October 2019. Available at: <https://www.pharmac.govt.nz/2019/09/18/SU.pdf>

Becton Dickinson Limited, New Zealand, Toll Free: 0800 572 468.

[bd.com](http://bd.com)

BD, the BD Logo and Micro-Fine are trademarks of Becton, Dickinson and Company or its affiliates. © 2020 BD. All rights reserved. BD-16634



For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.researchreview.co.nz](http://www.researchreview.co.nz)

## Establishment and validation of a risk prediction model for early diabetic kidney disease based on a systematic review and meta-analysis of 20 cohorts

**Authors:** Jiang W et al.

**Summary:** These authors used data from a meta-analysis of studies reporting on diabetic kidney disease risk factors in 41,271 patients with type 2 diabetes to derive a model for predicting this complication. Factors that were significantly predictive of diabetic kidney disease and were included in the model were age, BMI, smoking, diabetic retinopathy, HbA<sub>1c</sub> level, systolic BP, high-density lipoprotein cholesterol level, triglyceride levels and urinary albumin-to-creatinine ratio; estimated glomerular filtration rate was also predictive but was significantly heterogeneous among the studies so was not included in the model. The individual risk factors were assigned scores according to their weightings; the highest score was 37.0. Validation undertaken in an external cohort of Chinese patients with median follow-up of 2.9 years revealed respective sensitivity and specificity values of 0.847 and 0.677 at a cutoff value of 16.

**Comment:** Diabetic nephropathy is one of the most debilitating and costly complications of diabetes that we try to prevent. Currently we screen for the risk of developing nephropathy in people with diabetes by regular urine microalbumin testing. While this is useful for detecting early disease, and identifying people who need more aggressive BP and glycaemic management, it doesn't differentiate those at greatest risk or rapid progression of renal failure. Any tool that could optimise this would be very useful. This paper reports a risk prediction tool for diabetic kidney disease derived from readily available clinical data from over 40,000 people with type 2 diabetes. The scoring tool was then validated in a separate cohort. The parameters included in the model were all predictable factors, but the strength of the tool is in the relative weighting and collation of them together. This has the potential to be useful clinically, but as with any such tool, this will only be the case if it is easy to use in an automated practice management system, otherwise it is very unlikely to be actually used.

**Reference:** *Diabetes Care* 2020;43:925–33

[Abstract](#)

## A multinational, multicenter, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy of cyclical topical wound oxygen (TW02) therapy in the treatment of chronic diabetic foot ulcers

**Authors:** Frykberg RG et al., on behalf of the TW02 Study Group

**Summary:** Patients with diabetes and chronic diabetic foot ulcers (n=220) were randomised to multimodal cyclical pressure topical wound oxygen home therapy or sham therapy added to optimal standard care in the TW02 study. At first analysis, there was a significant difference between the active versus sham therapy arm for ulcer closure (41.7% vs. 13.5%; adjusted odds ratio 6.00 [97.8% CI 1.44, 24.93]), with a significantly greater likelihood of ulcer healing by week 12 (adjusted hazard ratio 4.66 [1.36, 15.98]) and a greater 12-month ulcer closure rate (56% vs. 27% [p=0.013]).

**Comment:** I confess that I know nothing about this treatment, but the study caught my eye because it was well designed and addressed an important issue that causes a lot of morbidity and cost. Topical oxygen therapy was >4 times more effective than standard care in healing ulcers at 12 weeks. This benefit was attenuated but still twice as likely to result in persistent closure of the ulcers at 12 months. This looks to be a highly effective treatment. It may already be being used around the country, but I have not come across it. It is something that should be considered and explored by podiatrists and multidisciplinary foot clinic teams.

**Reference:** *Diabetes Care* 2020;43:616–24

[Abstract](#)

**RACP MyCPD Program participants can claim one credit per hour** (maximum of 50 credits per year) for reading and evaluating Research Reviews.

**FOR MORE INFORMATION [CLICK HERE](#)**





## Effects of bariatric surgery in early- and adult-onset obesity in the prospective controlled Swedish obese subjects study

Authors: Kristensson FM et al.

**Summary:** This analysis of data from participants from the prospective Swedish Obese Subjects study sought to establish if obesity status at age 20 years has an influence on later-life bariatric surgery outcomes. Study participants were aged 37–60 years with BMI  $\geq 34$  kg/m<sup>2</sup> for men or  $\geq 38$  kg/m<sup>2</sup> for women at enrolment, with 2007 assigned to bariatric surgery and 2040 to usual care, and stratified as normal weight (BMI  $< 25$  kg/m<sup>2</sup>), overweight (25–29.9 kg/m<sup>2</sup>) or obese ( $\geq 30$  kg/m<sup>2</sup>), calculated using self-reported bodyweight values, at age 20 years. Small but statistically significant differences were seen for bodyweight reductions among the subgroups after bariatric surgery ( $p=0.032$  for interaction), with participants who were obese at age 20 years having the greatest reductions. For the respective subgroups with normal weight, overweight and obesity at aged 20 years, bariatric surgery was associated with increased likelihoods of type 2 diabetes remission (odds ratios 4.51, 4.90 and 5.58 [ $p=0.951$  for interaction]) and reduced type 2 diabetes incidence (0.15, 0.13 and 0.15 [ $p=0.972$  for interaction]), and reductions in microvascular complications independent of obesity status at age 20 years ( $p=0.650$  for interaction). Associations between bariatric surgery and CV disease were similar among the subgroups ( $p=0.674$  for interaction), as were surgical complications.

**Comment:** There is now overwhelming evidence that bariatric surgery is a highly effective treatment for type 2 diabetes. This is true for several different procedures and for people of different levels of obesity at the time of surgery. The Swedish Obesity Study is the longest running prospective study of bariatric surgery and although not randomised has given us a wealth of data and in insight into the relationship between obesity and diabetes and the longitudinal effects of surgery on that. This report focuses on the question of whether early obesity influences the metabolic benefits of surgery much later in life. The hypothesis being that early obesity may diminish the benefits. However, it is interesting that that does not appear to be the case. It supports the idea that  $\beta$ -cell function and failure are the most important factors and that obesity and insulin resistance reveals or hastens the metabolic decline/reversal. This is further supported by the observation that remission following surgery is less common in those already requiring insulin therapy – and thus are further down the pathway of  $\beta$ -cell failure. It's good to inherit an abundance of  $\beta$ -cells!

Reference: *Diabetes Care* 2020;43:860–6

[Abstract](#)

## Outcomes of a church-based lifestyle intervention among Australian Samoans in Sydney

Authors: Ndwiga DW et al.

**Summary:** These researchers reported on the effectiveness of the Le Taaeo Afua diabetes prevention programme, a culturally adapted, church-based lifestyle intervention delivered by community coach and peer support facilitators aimed at preventing and promoting self-management of type 2 diabetes, and targeted towards Samoans living in Australia. Of 107 participants enrolled, 68 (63.5%; mean age 48.9 years; 57.2% female) had before and after intervention data for analysis. Participants with diabetes experienced a fall from baseline in HbA<sub>1c</sub> level after completing the programme (from 65 to 57 mmol/mol, or from 8.1% to 7.4% [ $p=0.040$ ]); the reduction for those with newly diagnosed diabetes did not reach statistical significance (from 64 to 54 mmol/mol, or 8.0% to 7.1% [ $p=0.131$ ]). Among participants without diabetes, weekly moderate and vigorous physical activity increased (from 316.1 to 562.4 min [ $p=0.007$ ]) as did their knowledge of diabetes ( $p<0.001$ ). There was no significant change for BP, BMI or waist circumference associated with completion of the programme.

**Comment:** In NZ, the highest rates of type 2 diabetes are seen in the Pacific population, who also have high rates of diabetes complications. Therefore anything that might be effective in preventing diabetes or assisting in self-management and improved outcomes needs to be tried and assessed. Because the church community is very important for many Pacific people, it is often touted as an environment where interventions could be delivered. However, the evidence to support the effectiveness of such an approach has been lacking. It is therefore great to see this study. The authors acknowledge that this is an observational cohort design and that an RCT is required, but the initial results are encouraging that a community approach, delivered in a church setting, can be effective in improving health measures for Pacific people with and without diabetes.

Reference: *Diabetes Res Clin Pract* 2020;160:108000

[Abstract](#)

## A food-based, low-energy, low-carbohydrate diet for people with type 2 diabetes in primary care

Authors: Morris E et al.

**Summary:** Thirty-three patients with type 2 diabetes and BMI  $\geq 30$  kg/m<sup>2</sup> were randomised 2:1 to an 800–1000 kcal/day, food-based, low-carbohydrate (<26% energy) diet for 8 weeks, followed by a 4-week weight maintenance period and four 15- to 20-minute appointments with a nurse, or to usual care, in this feasibility trial; 32 participants completed follow-up. Compared with usual care, the intervention was associated with greater reductions in mean weight loss (9.5 vs. 2kg [ $p<0.001$ ]) and mean HbA<sub>1c</sub> level (16.3 vs. 0.7 mmol/mol [ $p<0.001$ ]).

**Comment:** The popularity of reduced carbohydrate diets ebbs and flows over time. There have been many iterations of these diets and its extreme version, the 'keto diet', is currently de rigueur. Whenever you mention 'low-carb diets' in nutrition circles, you get a very polarised response. However, there is no doubt that for some individuals, following a low-carbohydrate diet is achievable, preferable and successful in facilitating weight control. For people with type 2 diabetes, the potential benefit of this approach is even greater, with less demand on pancreatic insulin production. This study is a feasibility study to establish whether prescription and support of a low-carbohydrate energy-restricted diet within primary care is achievable. The results were encouraging, with greater weight loss and impressive reductions in HbA<sub>1c</sub> level than standard care. It is of course important to realise that this was over 12 weeks and the real test is what happens at 12 months and 2 years. I'm sure the authors are already planning or conducting such a trial, and we await the outcome.

Reference: *Diabetes Obes Metab* 2020;22:512–20

[Abstract](#)

### Independent commentary by Professor Jeremy Krebs

MBChB, FRACP, MD



Professor Krebs is an Endocrinologist with a particular interest in obesity and diabetes. He is a Professor with the University of Otago, and former Director of the Clinical Research Diploma at Victoria University - which he established.

FOR FULL BIO [CLICK HERE](#).



# Rethink Obesity®

Webinar Series

Don't miss the opportunity to learn from the experts about the management of people living with obesity

REGISTER NOW

Sponsored by 

Rethink Obesity® webinars are a CPD activity delivered by Ogilvy Health, an authorised provider of accredited activities, in partnership with the RACGP. It is also SCOPE accredited by the World Obesity Federation and proudly sponsored by Novo Nordisk.





## Inhibition of food craving is a metabolically active process in the brain in obese men

Authors: Wang G-J et al.

**Summary:** Using fluorodeoxyglucose-PET, brain responses during attempted cognitive inhibition of craving on exposure to food cues were compared between 16 obese men and 11 age-matched nonobese men in this research. While in a food-deprived state, the men's brain glucose metabolism was measured with no food stimulation, food stimulation with no inhibition and food stimulation with attempted inhibition on separate days, with individualised favourite food items presented prior to and after the fluorodeoxyglucose injection for 40 minutes. In both groups, food stimulation versus no stimulation was associated with increased glucose metabolism in the inferior and superior frontal gyri, default mode network and cerebellum, and attempted inhibition versus no inhibition was associated with suppressed metabolism in the right subgenual anterior cingulate, orbitofrontal areas and bilateral insula and temporal gyri. However, the obese men exhibited increased metabolism in the pregenual anterior cingulate cortex and caudate during attempted inhibition versus no inhibition, whereas the nonobese men did not. Negative correlations between changes in food desire from no inhibition to attempted inhibition and changes in metabolism in the pregenual anterior cingulate cortex/caudate were also seen in the obese men and not in their nonobese counterparts.

**Comment:** Well this is a fun little paper. Energy intake is such a complex interaction between genetics, environment and behaviour. How this battle plays out largely determines our weight. Of course energy expenditure is the other critical player. This is an interesting experiment to determine whether there are any important differences between obese and lean men in terms of brain activity during active attempted inhibition of food intake. The use of PET scanning to measure actual metabolic brain activity is a strength. It shows that for obese men, there is more interaction between food stimuli and brain activity, and a more energy-dependant process to overcome the positive stimulus of food. We are hard-wired to conserve energy, so this observation may in part explain how obese men may be less successful in their attempts to resist food when available. I'm just trying to decide which of my many favourite foods I would choose for this experiment!

Reference: *Int J Obes* 2020;44:590-600

[Abstract](#)

## Association of glucose-lowering medications with cardiovascular outcomes

Authors: Zhu J et al.

**Summary:** This umbrella review and evidence map included 232 meta-analyses of RCTs examining the CV safety of ten classes of antidiabetes drugs. Six risk and 38 protective associations with high evidence strength were identified. Glimepiride was associated with significantly increased stroke risk, rosiglitazone with MI and HF risk and pioglitazone with HF risk. The protective associations included significantly lower risks of: i) major adverse CV events with GLP-1 receptor agonists (including albiglutide, exenatide, liraglutide and semaglutide specifically), SGLT-2 inhibitors (including canagliflozin and empagliflozin specifically) and pioglitazone; ii) death from CV disease with GLP-1 receptor agonists and SGLT-2 inhibitors (including canagliflozin and empagliflozin specifically); iii) MI with GLP-1 receptor agonists (including albiglutide specifically), SGLT-2 inhibitors and pioglitazone; iv) HF with GLP-1 receptor agonists (including albiglutide specifically) and SGLT-2 inhibitors (including canagliflozin, dapagliflozin and empagliflozin specifically); and v) stroke with GLP-1 receptor agonists (including dulaglutide and semaglutide specifically) and pioglitazone.

**Comment:** I have included this study for two reasons. Firstly, it pulls together all of the evidence for positive and negative effects of diabetes medications on CV outcomes, and secondly because I couldn't resist the cute concept of an 'umbrella review'! There really is so much evidence now for the broad benefits of the SGLT-2 inhibitors and the GLP-1 agonists. As this review reports, this is in contrast to adverse effects of the sulfonylureas routinely used as the comparator in Pharma trials, and the thiazolidinediones; although pioglitazone has mixed effects. These findings continue to keep the focus on the need for PHARMAC to fund either or both SGLT-2 inhibitors and GLP-1 agonists. It also raises concerns that the US FDA has removed their requirement for new drugs in the diabetes area to undergo CV outcome trials. It was only because of this requirement, brought in after the postmarketing negative effects of rosiglitazone were reported, that we have had these major trials conducted, which have given us such useful evidence for these new drugs. Sadly, without the FDA requirement, I think it is unlikely that the Pharma industry will continue to conduct such trials and they are unlikely to be funded by other sources.

Reference: *Lancet Diabetes Endocrinol* 2020;8:192-205

[Abstract](#)

## A Practical Guide to Insulin initiation, titration and escalation

### Research Review E-Learning Module

It has been endorsed by both the RNZCGP and CNN(NZ) for 1 hour of professional development.

The module is based on a summary of a recent practical presentation for busy clinicians given by Auckland endocrinologist **Dr Carl Peters**.

#### PRESENTATION SUMMARY

This summary covers:

- Appropriate HbA1c targets for different patient populations
- Tips for successful initiation of insulin
- Advice for titrating basal insulin to target
- When to intensify insulin therapy
- Advice for titrating meal-time insulins
- Patients who require insulin management in secondary care



GPs: COMPLETE THIS MODULE AT NO COST



NURSES: COMPLETE THIS MODULE AT NO COST



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

**Independent Content:** The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

**Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

**Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.



[CLICK HERE](#)  
to read previous issues of  
Diabetes & Obesity Research Review